Eating More Fiber Changes Your Bile Acids in Ways That Help Melanoma Immunotherapy Work

Eating more fiber has long been associated with better outcomes in cancer immunotherapy, but the biological mechanism has remained frustratingly vague. A new analysis from the DIET trial, published in the Journal of Clinical Oncology, puts a sharper molecular picture on that link: dietary fiber appears to dampen the gut microbiome's conversion of primary bile acids into secondary bile acids, and that shift tracks with improved responses to immune checkpoint blockade (ICB) in melanoma patients.

High-Fiber Diet Reduces Secondary Bile Acids in Melanoma Patients on ICB

The core finding comes from untargeted metabolomics run on blood serum from 43 melanoma patients enrolled in the DIET trial (NCT04645680). Patients randomized to the high-fiber arm gradually increased their daily intake from 30 grams to 50 grams over the course of the study, while controls stayed at 20 grams per day for up to 10 weeks. The metabolomics data showed a statistically significant reduction (p<0.05) in bile acids and their glycine- and taurine-conjugated derivatives in the high-fiber group. Targeted bile acid profiling confirmed the picture: unconjugated secondary bile acids, including deoxycholic acid, lithocholic acid, and ursodeoxycholic acid, all dropped. The ratio of secondary to primary bile acids also fell, pointing to reduced microbial conversion of primary bile acids like cholic acid and chenodeoxycholic acid.

This matters because earlier observations linking fiber intake to melanoma immunotherapy outcomes were based largely on epidemiological patterns. The DIET trial is one of the few randomized trials to measure what actually changes in the body when patients deliberately increase their fiber intake during ICB treatment.

Why Bile Acids Are a Plausible Lever for Anti-Tumor Immunity

Bile acids are not just digestive chemicals. Secondary bile acids in particular, produced when gut bacteria chemically modify primary bile acids, are potent signaling molecules that interact with immune cells throughout the body. A growing body of research shows that microbiota-transformed bile acids influence both innate and adaptive immune cells within the tumor microenvironment, shaping whether the immune system mounts an effective anti-tumor response or stays suppressed.

The DIET trial findings add a dietary dimension to that biology. By reducing fiber-fermenting bacteria's substrate or altering microbial community composition, a high-fiber diet appears to pull down the secondary bile acid pool. The data also suggest reduced hepatic conjugation of bile acids: the ratio of conjugated to unconjugated bile acids dropped in the high-fiber arm, implying changes that extend beyond the gut lumen into systemic metabolism. Related preclinical work has shown that specific microbiota-derived bile acids can directly modulate T cell function; for instance, taurodeoxycholic acid has been found to restore CD8+ T cell anti-tumor activity when ICB efficacy is disrupted. The DIET trial data suggest the opposite direction may also be true: reducing certain secondary bile acids could relieve immunosuppressive pressure.

How Mouse Avatar Models Strengthened the Causal Case

Correlating bile acid changes with ICB response in patients is suggestive but not causal. The DIET trial team addressed this by using mouse avatar models of melanoma. Mice received fecal microbiota transplants (FMT) taken from trial participants either before or after they completed the high-fiber dietary intervention. Mice that received post-diet FMT showed improved ICB responses compared to those receiving pre-diet FMT. Critically, the post-diet FMT mice also exhibited decreased secondary-to-primary bile acid ratios in circulation, mirroring what was seen in the human participants.

This FMT experiment is important because it moves the argument from correlation to a testable mechanism. If the bile acid shift were merely a passenger rather than a driver of the immune response, transferring the post-diet microbiome to naive mice would not necessarily reproduce the ICB benefit. The fact that it does, alongside the bile acid shift, supports the hypothesis that microbial bile acid metabolism is a meaningful part of the pathway.

Limitations: Small Sample and Mechanistic Gaps

The study enrolled 45 patients total, with the metabolomics analysis drawing on paired samples from just 6 patients in the high-fiber arm and 8 in the control arm. That is a small number on which to build a mechanistic story, and the authors acknowledge that the findings require validation in larger cohorts. The mouse avatar models, while mechanistically valuable, involve melanoma cell lines grafted into immunocompromised animals, a context that simplifies the complexity of human tumor immunology.

It also remains unclear exactly which bacterial species are primarily responsible for the observed bile acid changes, or whether the reduction in specific secondary bile acids like deoxycholic acid is the active variable or a proxy for something else happening in the microbial community. The direction of hepatic conjugation changes and their downstream immune consequences will need dedicated mechanistic studies to untangle.

What Comes Next for Fiber and Immunotherapy Research

The DIET trial (NCT04645680) was designed partly to establish the safety and feasibility of pushing fiber intake to 50 grams per day in melanoma patients on ICB, and it did that. The bile acid findings now give researchers a specific metabolic readout to track in future trials. The full DIET study protocol is a randomized, double-blind, controlled feeding design, which positions it well for mechanistic follow-up.

Beyond melanoma, the CANS trial is already testing whether high fiber and fermented foods can improve the gut microbiome in patients with stage IIB-IIIC melanoma and stage IB-IIIC non-small cell lung cancer receiving immune checkpoint inhibitors, expanding the dietary intervention hypothesis to a second tumor type. If bile acid profiling proves to be a reliable biomarker of response, it could eventually inform personalized dietary recommendations or point toward microbiome-targeted interventions as adjuncts to ICB therapy. For now, the DIET trial data offer one of the clearest molecular explanations yet for why something as accessible as dietary fiber might influence whether a cancer patient responds to immunotherapy.